Current FDA labeling does not mandate routine liver enzyme monitoring for all patients taking semaglutide, as the medication is not associated with significant hepatotoxicity risk
The findings suggest semaglutide may be a preferred choice of GLP-1 RA for reducing cardiovascular risk in type 2 diabetes, offering clinicians valuable evidence to guide therapeutic decisions
For this study, researchers used a mouse model to determine how GLP-1 medications like Ozempic affected lean muscle mass
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
For researchers evaluating providers, platforms like SeekPeptides provide independent analysis of various GLP-1 programs and vendor reviews, helping you compare options based on verified data rather than marketing claims